Cyclops®

  • Convenient
  • Reliable
  • Easy-to-use
  • Easy-to-carry
  • Hygienic
  • Less Cough

About us

PureIMS is a clinical stage pharmaceutical company focused on developing and commercializing innovative inhaled therapies, based on its proprietary dry powder inhaler Cyclops®. The focus is on the treatment of systemic and respiratory diseases with significant unmet medical need. The company’s leadership team consists of seasoned life sciences executives who bring long-lasting and complementary experience in leading drug development, addressing applicable scientific issues and pursuing commercial and business development & licensing opportunities. They obtained their experience in leading positions with mid-size and top-5 global Pharma companies, and with successful service providers. PureIMS’ lead candidate, Levodopa Cyclops®, is in the final development stage as rescue therapy for OFF-episodes in Parkinson’s disease. One product, Colistin Cyclops®, is already marketed and reimbursed under a named patient program for the treatment of cystic fibrosis patients. Other clinical programs – including Epinephrine Cyclops® for (food) allergy and impending anaphylaxis – are being explored in an early clinical stage. PureIMS also supports pharma/biotech partners, applying the Cyclops®-based inhalation route for their drug of choice.

our team

Jaap Wieling

PhD, Chief Executive Officer

Dr. Wieling brings 30 years of experience as an executive and entrepreneur in (bio)pharmaceutical research and development (TNO, DSM, PRA/ICON, Xendo, QPS and BiosanaPharma). He is a seasoned expert in building effective and efficient product and platform development businesses and serves on the board and advisory committee of various (bio)pharmaceutical companies and (biopharmaceutical) service industries. For many years he has been invited university lecturer on pharmaceutical product development. He holds a BSc degree in chemistry, an MSc degree in pharmacology and a PhD degree in Mathematics and Natural Sciences from Groningen University, The Netherlands.

Floris Grasmeijer

PhD, Principal Scientist

Floris Grasmeijer is a pharmacist and is responsible for formulation and device development in his role as Principal Scientist at PureIMS. He performed a PhD in inhalation technology at the University of Groningen, after which he there continued his studies as a post-doctoral researcher. Besides his expertise in formulations and devices, Floris also has experience with the preparation of clinical trials. Floris is involved with PureIMS from the start: “It is very motivating to put theory to practice; to take the knowledge about powders and inhalers and use it to quickly pinpoint and solve problems as they arise and to develop products that actually make a difference to patients.”

Marcel Hoppentocht

PhD, Head of Program Management

Marcel Hoppentocht is a pharmacist and in view of his broad interest and organizational capacities his role as Head of Program Management suits him well. He performed a PhD in inhalation technology at the University of Groningen, during which the Cyclops® DPI was developed and a first clinical trial with Cyclops® was conducted. He continued as a post-doctoral researcher for two years during which he was Project Leader of formulation and inhaler development within the Innovative Medicines Initiative (IMI) iABC project dedicated to developing inhaled antibiotics. Marcel is involved with PureIMS from the start: “Making Cyclops® available to many patients and improving their quality of life, would be a dream come true.

Wouter Dijkstra

Head of Production

Wouter Dijkstra is a pharmacist and responsible for production in his role as Head of Production at PureIMS. He studied pharmacy at the University of Groningen, after which he has worked for several pharmaceutical companies in different roles. Wouter has experience with manufacturing and release of Investigational Medicinal Products and compounded products. Wouter is involved with PureIMS since 2019: “It is a privilege to support the development of an amazingly innovative Dry Powder Inhaler and make a change for patients in need.” 

Frank Lambert

Executive Director Commercialization

Per start 2023 Frank Lambert serves PureIMS as Executive Director Commercialization to support the company’s strategy to commercialize its Cyclops® DPI for partnering and co-development with pharma/biotech companies. Studying Human Movement Sciences in 1988 he graduated from the faculty of Medical Sciences of the University of Groningen. Frank is a seasoned business development professional with a 20+ years record in commercial Contract Research Organizations (CRO) as ICON plc. and before PRA HealthSciences. Before he managed an Academic CRO at the University Medical Center in Groningen for a decade. Having lived and operated as Director of Business Development for four years in the United States, he returned to the Netherlands in 2008 to continue his activities in Europe and Asia-Pacific. Frank acts as First Point of Contact for potential partners showing interest in developing combination products with PureIMS. (flambert@pureims.com / M: +31 6517 07 297)

Roelof Kuper

Senior Technician

Roelof Kuper is a biotechnologist and works on the further development of PureIMS’s inhalation platform, Cyclops®. Roelof obtained a BSc in Biotechnology and a MSc in Molecular Life Science. Before joining PureIMS in March 2023 he has worked for different biotech companies where he was responsible for the development and implementation of various processes and new technologies in early and late-stage drug development programs. His strong research background, including topics in molecular biology, genetics and protein engineering are a valuable addition to the team.  “The opportunity to further develop Cyclops® to improve patient care and maximize quality of life is a great thing to do”.

Wouter van Gammeren

Finance Manager

Wouter van Gammeren is responsible for finance at PureIMS. Wouter obtained his Masters of Business Administration, specializing in Strategy and Innovation, at the University of Groningen in 2012. Since then, Wouter has worked as consultant in the field of business controlling and finance for several years, mainly for start-up companies in the life science sector. Since 2023 Wouter joined PureIMS as finance manager.

Sebastian Klamer

QA Pharmacist

Sebastian Klamer is an experienced pharmacist with a decade of expertise in Quality Assurance, R&D, Regulatory Affairs, and Product Release. He is passionate about developing pharmaceutical products that enhance patient health while ensuring their safety and user-friendliness. The opportunity to contribute to the advancement of healthcare through these innovations genuinely excites him.

Collaborations

University of Groningen

  • Department of Pharmaceutical Technology and Biopharmacy

University Medical Center Groningen (UMCG)

  • Department of Lung Diseases and Tuberculosis
  • Department of Allergology
  • Dr. J.N.G. Oude Elberink

Beatrix Children's Hospital (part of UMCG)

  • Pediatric Pulmonology and Pediatric Allergology

Punt voor Parkinson

Martini Hospital Groningen

  • Department of Pharmacy / Clinical Pharmacy

Interventional Medical Device Solutions

eLabNext

Harro Höfliger Verpackungsmaschinen GmbH

Contact Us

Ceintuurbaan Noord 152
9301 NZ Roden
The Netherlands
T: +31 (0)50 – 2053 325
F: +31 (0)50 – 2053 326
E: info@pureims.com

Social media

Linkedin-in Youtube

Inspiration by Patients

CALL US NOW
© 2024 pureims